<DOC>
	<DOCNO>NCT01923168</DOCNO>
	<brief_summary>The purpose study determine whether treatment PI3K inhibitor plus letrozole lead increase pathologic clinical response Objective Response Rate compare treatment placebo plus letrozole patient Breast cancer</brief_summary>
	<brief_title>Study Letrozole With Without BYL719 Buparlisib , Neoadjuvant Treatment Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>1 . Patient adult , female â‰¥ 18 year old time inform consent 2 . Patient histologically and/or cytologically confirm diagnosis breast cancer 3 . Patient postmenopausal . 4 . Patient T1cT3 , N , M0 , operable breast cancer 5 . Patients must measurable disease 6 . Patient diagnostic biopsy available analysis PIK3CA mutation Ki67 level . 7 . Patient estrogenreceptor and/or progesterone positive breast cancer per local laboratory test 8 . Patient HER2 negative breast cancer define negative situ hybridization test IHC status 0 1+ per local laboratory test 1 . Patient locally recurrent metastatic disease 2 . Patient receive systemic therapy ( e.g . chemotherapy , target therapy , immunotherapy ) radiotherapy current breast cancer disease randomization . 3 . Patient type 1 diabetes mellitus adequately control type 2 diabetes mellitus 4 . History acute pancreatitis within 1 year study entry 5 . Uncontrolled hypertension 6 . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Breast Cancer , Pathological Complete Response , neoadjuvant , hormone receptor-positive</keyword>
</DOC>